Degron Therapeutics
Shanghai
About Degron Therapeutics
Degron Therapeutics is a drug discovery platform. They provide the discovery and development of a new class of targeted protein degradation therapeutics and small molecule molecular glue degrader drugs. Degron Therapies aspires to be a global leader in the discovery and development of small molecule molecular glue degrader (MGD) medicines, a new class of targeted protein degradation therapeutics. Degron has assembled a team of world-class executives and scientific leaders to apply its scientific expertise to the identification and validation of disease targets, particularly those that are inaccessible to conventional small molecule inhibitors, as well as novel selective MGD compounds to address unmet medical needs across all therapeutic areas.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $54.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Dec 2025)
- Website: degrontx.com
- Phone: 021-61215873
Industries & Categories
Biotechnology, Health Care, Oncology
Canonical: https://fsome.com/organization/degron-therapeutics-112931 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.